AI Insight
A new study has found that nearly 1 in 6 children taking GLP-1 receptor agonist medications for weight loss, prediabetes, or type 2 diabetes developed diagnosed nutritional deficiencies within one year of starting treatment. Vitamin D deficiency was the most common, affecting approximately 12% of young patients. These medications include Victoza, Saxenda, Trulicity, and Ozempic.
Why it matters
This finding highlights a potentially serious side effect of GLP-1 medications in pediatric populations that may require monitoring and nutritional supplementation. Healthcare providers prescribing these drugs to children may need to implement routine screening for nutritional deficiencies and consider preventive interventions.
Understand the Science
Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.
Source: GLP-1 weight loss and diabetes drugs linked to nutritional deficiencies in nearly 1 in 6 children